ClinicalTrials.gg
CompletedNCT03428100BREEZE-AD4Updated May 14, 2024Results posted

A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable

A Phase 3 interventional study of Baricitinib and Placebo in Atopic Dermatitis, sponsored by Eli Lilly and Company. Completed at 103 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
463
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing baricitinib in Dermatitis, Atopic — 1 open to participants now, 1 under way, none of them phase 3. baricitinib · Dermatitis, Atopic.

Enrollment
5th of 11
463 · median 440
Started
2018
with 4 others
Phase 3
8 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
9 of 11
Eli Lilly and Company

Among the 11 studies testing baricitinib in Dermatitis, Atopic, this one is the 5th largest by enrollment, is one of 5 that started in 2018, is one of 8 in phase 3, and was the 5th registered.

Dermatitis, Atopic

1,592 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 11 studies testing baricitinib in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About baricitinib

baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing baricitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of baricitinib in combination with topical corticosteroids in participants with moderate to severe atopic dermatitis who have experienced failure to cyclosporine or are intolerant to, or have contraindication to cyclosporine.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • eczema
  • atopic eczema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have been diagnosed with moderate to severe Atopic Eczema (Atopic Dermatitis) for at least 12 months.
  • Have had inadequate response to existing topical (applied to the skin) medications within 6 months preceding screening.
  • Are willing to discontinue certain treatments for eczema (such as systemic and topical treatments during a ).
  • Agree to use emollients daily.
  • Have a medical to cyclosporine, or had intolerance and/or unacceptable toxicity or inadequate response to cyclosporine in the past.

Exclusion criteria

Exclusion Criteria:

  • Are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus), or a history of erythrodermic, , or unstable skin disease that requires frequent hospitalizations and/or intravenous treatment for skin infections.
  • A history of eczema herpeticum within 12 months, and/or a history of 2 or more episodes of eczema herpeticum in the past.
  • Participants who are currently experiencing a skin infection that requires treatment, or are currently being treated, with topical or systemic antibiotics.
  • Have any serious illness that is anticipated to require the use of systemic or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma).
  • Have been treated with the following therapies:

    • Monoclonal antibody for less than 5 half-lives prior to randomization.
    • Received prior treatment with any oral Janus kinase (JAK) inhibitor less than 4 weeks prior to randomization.
    • Received oral corticosteroids within 4 weeks prior to randomization or parenteral corticosteroids administered by intramuscular or intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study.
    • Have had an intra-articular corticosteroid injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization.
  • Have high blood pressure characterized by a repeated systolic blood pressure >160 millimeters of mercury (mm Hg) or diastolic blood pressure >100 mm Hg.
  • Have had major surgery within the past eight weeks or are planning major surgery during the study.
  • Have experienced any of the following within 12 weeks of screening: venous thromboembolic event (VTE), myocardial infarction (MI), unstable ischemic heart disease, stroke, or Stage III/IV heart failure.
  • Have a history of recurrent (≥ 2) VTE or are considered at high risk of VTE as deemed by the investigator.
  • Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, lymphoproliferative disease or neuropsychiatric disorders or any other serious and/or unstable illness.
  • Have a current or recent and/or clinically serious viral, bacterial, fungal, or parasitic infection including but not limited to herpes zoster, tuberculosis.
  • Have specific laboratory abnormalities related to thyroid, renal and liver function, or blood cells.
  • Have received certain treatments that are .
  • Pregnant or breastfeeding.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
463 participants (actual)

Study arms

  • Experimental
    4 mg Baricitinib

    4 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.

    Drug: Baricitinib · Drug: Placebo · Drug: Topical corticosteroid

  • Experimental
    2 mg Baricitinib

    2 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.

    Drug: Baricitinib · Drug: Placebo · Drug: Topical corticosteroid

  • Experimental
    1 mg Baricitinib

    1 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.

    Drug: Baricitinib · Drug: Placebo · Drug: Topical corticosteroid

  • Placebo comparator
    Placebo

    Placebo administered orally once daily in combination with topical corticosteroids. Additional Placebo administered orally to maintain the blind.

    Drug: Placebo · Drug: Topical corticosteroid

  • Experimental
    Long Term Extension(LTE) Substudy 4mg Baricitinib to 4mg Baricitinib (Responders/Partial Responders)

    4 mg Baricitinib administered orally once daily (continued previous dose) in combination with topical corticosteroids. Placebo administered orally to maintain the blind.

    Drug: Baricitinib · Drug: Placebo · Drug: Topical corticosteroid

  • Experimental
    LTE Substudy 4 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)

    4 mg Baricitinib rerandomized to 2 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.

    Drug: Baricitinib · Drug: Placebo · Drug: Topical corticosteroid

  • Experimental
    LTE Substudy 2 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)

    2 mg Baricitinib rerandomized to 2 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.

    Drug: Baricitinib · Drug: Placebo · Drug: Topical corticosteroid

  • Experimental
    LTE Substudy 2 mg Baricitinib to 1 mg Baricitinib (Responders/Partial Responders)

    2 mg Baricitinib rerandomized to 1 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.

    Drug: Baricitinib · Drug: Placebo · Drug: Topical corticosteroid

  • Experimental
    LTE 4 mg Baricitinib (Responders/Partial Responders) - Did Not Enter Substudy

    4 mg Baricitinib administered orally once daily (continued previous dose) in combination with topical corticosteroids. Placebo administered orally to maintain the blind.

    Drug: Baricitinib · Drug: Placebo · Drug: Topical corticosteroid

  • Experimental
    LTE 2 mg Baricitinib (Responders/Partial Responders) - Did Not Enter Substudy

    2 mg Baricitinib administered orally once daily (continued previous dose) in combination with topical corticosteroids. Placebo administered orally to maintain the blind.

    Drug: Baricitinib · Drug: Placebo · Drug: Topical corticosteroid

  • Experimental
    LTE 1 mg Baricitinib (Responders/Partial Responders) - Did Not Enter Substudy

    1 mg administered orally once daily (continued previous dose) in combination with topical corticosteroids. Placebo administered orally to maintain the blind.

    Drug: Baricitinib · Drug: Placebo · Drug: Topical corticosteroid

  • Placebo comparator
    LTE Placebo (Responders/Partial Responders) - Did Not Enter Substudy

    Placebo administered orally once daily (continued previous dose) in combination with topical corticosteroids. Additional placebo administered orally to maintain the blind.

    Drug: Placebo · Drug: Topical corticosteroid

  • Experimental
    LTE 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy

    4 mg administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.

    Drug: Baricitinib · Drug: Placebo · Drug: Topical corticosteroid

  • Experimental
    LTE 2 mg Baricitinib to 2 mg Baricitinib (Non-responders) - Did Not Enter Substudy

    2 mg Baricitinib rerandomized to 2 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.

    Drug: Baricitinib · Drug: Placebo · Drug: Topical corticosteroid

  • Experimental
    LTE 2 mg Baricitinib to 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy

    2 mg Baricitinib rerandomized to 4 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.

    Drug: Baricitinib · Drug: Placebo · Drug: Topical corticosteroid

  • Experimental
    LTE 1 mg Baricitinib to 2 mg Baricitinib (Non-responders) - Did Not Enter Substudy

    1 mg Baricitinib rerandomized to 2 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.

    Drug: Baricitinib · Drug: Placebo · Drug: Topical corticosteroid

  • Experimental
    LTE 1 mg Baricitinib to 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy

    1 mg Baricitinib rerandomized to 4 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.

    Drug: Baricitinib · Drug: Placebo · Drug: Topical corticosteroid

  • Experimental
    LTE Placebo to 2 mg Baricitinib (Non-responders) - Did Not Enter Substudy

    Placebo rerandomized to 2 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.

    Drug: Baricitinib · Drug: Placebo · Drug: Topical corticosteroid

  • Experimental
    LTE Placebo to 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy

    Placebo rerandomized to 4 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.

    Drug: Baricitinib · Drug: Placebo · Drug: Topical corticosteroid

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (Placebo, 2 mg or 4 mg Baricitinib)

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving EASI75 (Placebo, 1 mg Baricitinib)

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score. Missing values were imputed using Non-Responder Imputation (NRI), where non-responders were participants who permanently discontinue, are rescued, or are without at least 1 post-baseline observation.

    Time frame: Week 16

  2. Percentage of Participants Achieving IGA of 0 or 1 With a ≥ 2 Point Improvement

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

    Time frame: Week 16

  3. Percentage of Participants Achieving EASI90

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI90 is defined as a ≥ 90% improvement from baseline in the EASI score.

    Time frame: Week 16

  4. Percent Change From Baseline in EASI Score

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). Least Squares Mean (LSM) were calculated using mixed model repeated measures (MMRM) model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline score and baseline score-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  5. Percentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)

    The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3)oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with a visual analogue scales (VAS) where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. The SCORAD75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the SCORAD score.

    Time frame: Week 16

  6. Percentage of Participants Achieving a 4-Point Improvement in Itch Numeric Rating Scale (NRS)

    The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.

    Time frame: Week 16

  7. Change From Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS)

    The ADSS is a 3-item, participant-administered questionnaire developed to assess the impact of itch on sleep including difficulty falling asleep due to itch, frequency of waking due to itch, and difficulty getting back to sleep last night due to itch. Item 2 frequency of waking last night is reported by selecting the number of times they woke up each night, ranging from 0 to 29 times, where the higher a number indicates a worse outcome. The ADSS is designed to be completed daily, using a daily diary, with respondents thinking about sleep "last night." Each item is scored individually. LS Mean were calculated using an MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  8. Change From Baseline in Skin Pain NRS

    Skin Pain NRS is a participant-administered,11-point horizontal scale anchored at 0 and 10, with 0 representing "no pain" and 10 representing "worst pain imaginable." Overall severity of a participant's skin pain is indicated by selecting the number, using a daily diary, that best describes the worst level of skin pain in the past 24 hours. LS Mean were calculated using MMRM model includes treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  9. Percentage of Participants Achieving IGA of 0 or 1 With a >=2-point Improvement

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

    Time frame: Week 24

  10. Percentage of Participants Achieving EASI50

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI50 is defined as a ≥ 50% improvement from baseline in the EASI score.

    Time frame: Week 16

  11. Percentage of Participants Achieving EASI75

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

    Time frame: Week 24

  12. Percentage of Participants Achieving IGA of 0

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

    Time frame: Week 16

  13. Change From Baseline in SCORAD

    The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. LS Mean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  14. Percentage of Participants Achieving SCORAD90

    The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3)oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with a visual analogue scales (VAS) where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. The SCORAD90 responder is defined as a participant who achieves a ≥ 90% improvement from baseline in the SCORAD score.

    Time frame: Week 16

  15. Change From Baseline in Body Surface Area (BSA) Affected

    The BSA affected by AD will be assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage will be reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Use the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSAhead and neck + 0.3\*BSAtrunk + 0.2\* BSAupper limbs + 0.4\*BSAlower limbs. LS Mean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  16. Percentage of Participants Developing Skin Infections Requiring Antibiotic Treatment

    Percentage of participants developing skin infections requiring antibiotic treatment.

    Time frame: Week 16

  17. Mean Number of Days Without Topical Corticosteroids (TCS) Use

    The ANCOVA model includes treatment, region, and baseline disease severity (IGA) as factors.

    Time frame: Week 16

  18. Mean Gram Quantity of Low and Moderate Potency Background Topical Corticosteroid (TCS) Used (Tube Weights)

    Average weights of full tubes were used to determine the dispensed weights for each region. Returned tubes were weighed with cap without carton to determine the amount of TCS in grams (g) used at each visit. Analysis was done via analysis of variance (ANOVA), with geographic region, baseline disease severity, and treatment as factors in the model.

    Time frame: Week 16

  19. Percent Change From Baseline in Itch NRS

    The Itch NRS is a participant-administered, 11-point horizontal scale, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours. LS Means were calculated using MMRM model with treatment, region, baseline disease severity, visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  20. Percent Change From Baseline in Itch NRS at Week 24

    The Itch NRS is a participant-administered, 11-point horizontal scale, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours. LS Means were calculated using MMRM model with treatment, region, baseline disease severity, visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-interaction as fixed continuous effects.

    Time frame: Baseline, Week 24

  21. Change From Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM)

    The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life. LS Mean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by visit-interactions as fixed continuous effects.

    Time frame: Baseline, Week 16

  22. Change From Baseline in the Patient Global Impression of Severity - Atopic Dermatitis (PGI-S-AD) Score

    The PGI-S-AD is a single-item question asking the participant how they would rate their overall AD symptoms over the past 24 hours, using a daily diary. The 5 categories of responses are "(0) no symptoms", "(1) very mild", "(2) mild" "(3) moderate", and "(4) severe." LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  23. Change From Baseline on the Hospital Anxiety Depression Scale (HADS)

    The HADS is a participant-rated instrument used to assess both anxiety and depression. This instrument consists of 14 item questionnaire, each item is rated on a 4-point scale, giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale are considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7, 'normal.' LS Mean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  24. Change From Baseline in the Dermatology Life Quality Index (DLQI)

    The DLQI is a simple, participant-administered,10 question, validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period of this scale is over the last "week." Response categories include "not at all," "a little," "a lot," and "very much," with corresponding scores of 0, 1, 2, and 3, respectively, and unanswered or "not relevant" responses scored as "0." Scores range from 0 to 30 ("no impact on participant's life" to "extremely large effect on participant's life"), and a 4-point change from baseline is considered as the minimal clinically important difference threshold. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  25. Change From Baseline on the Work Productivity and Activity Impairment - Atopic Dermatitis (WPAI-AD) Questionnaire

    The WPAI-AD participant questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. The WPAI-AD consists of 6 items grouped in 4 domains: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment, that range from 0% to 100%, with higher values indicating greater impairment. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  26. Change From Baseline in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Index Score United States and United Kingdom Algorithm

    The EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1, with higher score indicating better health state. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  27. Change From Baseline on the European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Visual Analog Score (VAS)

    EQ-5D-5L is a 2-part measurement. The second part is assessed using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interactions as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  28. Percentage of Participants Achieving EASI75

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

    Time frame: Week 52

  29. Percent Change From Baseline in Itch NRS at Week 52

    The Itch NRS is a participant-administered, 11-point horizontal scale, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours. LS Means were calculated using MMRM model with treatment, region, baseline disease severity, visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-interaction as fixed continuous effects.

    Time frame: Baseline, Week 52

  30. Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (All Participants Entering the Substudy)

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using modified last observation carried forward (mLOCF).

    Time frame: Week 68

  31. Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (All Participants Entering the Substudy)

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using modified last observation carried forward (mLOCF).

    Time frame: Week 104

  32. Percentage of Participants With a Response of IGA 0, 1 Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (All Participants Entering the Substudy)

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

    Time frame: Week 68

  33. Percentage of Participants With a Response of IGA 0, 1 Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (All Participants Entering the Substudy)

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

    Time frame: Week 104

  34. Percentage of Participants With a Response of EASI75 From Baseline Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (All Participants Entering the Substudy)

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

    Time frame: Week 68

  35. Percentage of Participants With a Response of EASI75 From Baseline Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (All Participants Entering the Substudy)

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

    Time frame: Week 104

  36. Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (Participants Entering the Substudy With IGA 0 or 1)

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using modified last observation carried forward (mLOCF).

    Time frame: Week 68

  37. Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (Participants Entering the Substudy With IGA 0 or 1)

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using mLOCF.

    Time frame: Week 104

  38. Percentage of Participants With a Response of IGA 0 or 1 Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (Participants Entering the Substudy With IGA 0 or 1)

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using mLOCF.

    Time frame: Week 68

  39. Percentage of Participants With a Response of IGA 0, 1 Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (Participants Entering the Substudy With IGA 0 or 1)

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using mLOCF.

    Time frame: Week 104

  40. Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at Week 68 Participants Not Entered Into Substudy (All Participants)

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using mLOCF.

    Time frame: Week 68

  41. Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at Week 104 Participants Not Entered Into Substudy (All Participants)

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using mLOCF.

    Time frame: Week 104

  42. Percentage of Participants With a Response of IGA 0 or 1 Assessed at Week 68 - Participants Not Entered Into Substudy (All Participants)

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using mLOCF.

    Time frame: Week 68

  43. Percentage of Participants With a Response of IGA 0 or 1 Assessed at Week 104 - Participants Not Entered Into Substudy (All Participants)

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using mLOCF.

    Time frame: Week 104

  44. Percentage of Participants With A Response of EASI75 Assessed at Week 68 - Participants Not Entered Into Substudy (All Participants)

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

    Time frame: Week 68

  45. Percentage of Participants With A Response of EASI75 Assessed at Week 104 - Participants Not Entered Into Substudy (All Participants)

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

    Time frame: Week 104

  46. Time to Retreatment (Time to IGA ≥3) Randomized Downtitration (All Patients Entering the Substudy)

    Participants who entered the Substudy and relapsed with an IGA ≥3.

    Time frame: Week 52 Up to Week 200

07

Results

Posted Jan 19, 2021

Participant flow

Double-Blind Treatment Week 0 to Week 52
Participant flow — Double-Blind Treatment Week 0 to Week 52
MilestonePlacebo1 mg Baricitinib2 mg Baricitinib4 mg BaricitinibLong Term Extension(LTE) Substudy 4mg Baricitinib to 4mg Baricitinib (Responders/Partial Responders)LTE Substudy 4 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 1 mg Baricitinib (Responders/Partial Responders)LTE 4 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 2 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 1 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE Placebo (Responders/Partial Responders) - Did Not Enter SubstudyLTE 4 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE 2 mg Baricitinib to 2 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE 2 mg Baricitinib to 4 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE 1 mg Baricitinib to 2 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE 1 mg Baricitinib to 4 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE Placebo to 2 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE Placebo to 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy
Started939318592000000000000000
Received at least one dose of study drug939318492000000000000000
Completed728017385000000000000000
Not completed2113127000000000000000
Withdrew: Adverse event1031000000000000000
Withdrew: Lack of efficacy161076000000000000000
Withdrew: Protocol deviation0220000000000000000
Withdrew: Withdrawal by subject4000000000000000000
Withdrew: Physician decision0100000000000000000
Long-Term Extension Week 52 to Week 200
Participant flow — Long-Term Extension Week 52 to Week 200
MilestonePlacebo1 mg Baricitinib2 mg Baricitinib4 mg BaricitinibLong Term Extension(LTE) Substudy 4mg Baricitinib to 4mg Baricitinib (Responders/Partial Responders)LTE Substudy 4 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 1 mg Baricitinib (Responders/Partial Responders)LTE 4 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 2 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 1 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE Placebo (Responders/Partial Responders) - Did Not Enter SubstudyLTE 4 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE 2 mg Baricitinib to 2 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE 2 mg Baricitinib to 4 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE 1 mg Baricitinib to 2 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE 1 mg Baricitinib to 4 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE Placebo to 2 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE Placebo to 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy
Started000016162524722342924272613141112
Completed00002656355101644112
Not completed00001410201841729192321229131010
Withdrew: Adverse event0000041210103111200
Withdrew: Death0000000100000000000
Withdrew: Lack of efficacy0000223404409963441
Withdrew: Lost to follow-up0000000100021020010
Withdrew: Other0000002000010000021
Withdrew: Physician decision0000001000000000001
Withdrew: Study terminated by sponsor00001048837111186125317
Withdrew: Withdrawal by subject00002052061352510420

Outcome measures

PrimaryPercentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (Placebo, 2 mg or 4 mg Baricitinib)

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (Placebo, 2 mg or 4 mg Baricitinib)
percentage of participantsPlacebo2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (Placebo, 2 mg or 4 mg Baricitinib)17.2 (10.9 to 26.1)27.6 (21.6 to 34.4)31.5 (22.9 to 41.6)
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.071 · Odds ratio (or): 1.78 · 95% CI 0.95 to 3.32
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.031 · Odds ratio (or): 2.15 · 95% CI 1.07 to 4.30
SecondaryPercentage of Participants Achieving EASI75 (Placebo, 1 mg Baricitinib)

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score. Missing values were imputed using Non-Responder Imputation (NRI), where non-responders were participants who permanently discontinue, are rescued, or are without at least 1 post-baseline observation.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving EASI75 (Placebo, 1 mg Baricitinib)
percentage of participantsPlacebo1 mg Baricitinib
Percentage of Participants Achieving EASI75 (Placebo, 1 mg Baricitinib)17.2 (10.9 to 26.1)22.6 (15.3 to 32.1)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.427 · Odds ratio (or): 1.34 · 95% CI 0.65 to 2.77
SecondaryPercentage of Participants Achieving IGA of 0 or 1 With a ≥ 2 Point Improvement

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving IGA of 0 or 1 With a ≥ 2 Point Improvement
percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving IGA of 0 or 1 With a ≥ 2 Point Improvement9.7 (5.2 to 17.4)12.9 (7.5 to 21.2)15.1 (10.7 to 21.0)21.7 (14.5 to 31.2)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.513 · Odds ratio (or): 1.35 · 95% CI 0.55 to 3.35
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.242 · Odds ratio (or): 1.60 · 95% CI 0.73 to 3.53
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.030 · Odds ratio (or): 2.54 · 95% CI 1.09 to 5.90
SecondaryPercentage of Participants Achieving EASI90

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI90 is defined as a ≥ 90% improvement from baseline in the EASI score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving EASI90
percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving EASI906.5 (3.0 to 13.4)8.6 (4.4 to 16.1)10.3 (6.7 to 15.5)14.1 (8.4 to 22.7)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.611 · Odds ratio (or): 1.32 · 95% CI 0.45 to 3.83
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.325 · Odds ratio (or): 1.59 · 95% CI 0.63 to 3.99
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.100 · Odds ratio (or): 2.29 · 95% CI 0.85 to 6.14
SecondaryPercent Change From Baseline in EASI Score

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). Least Squares Mean (LSM) were calculated using mixed model repeated measures (MMRM) model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline score and baseline score-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Geometric least squares mean · percent change
Percent Change From Baseline in EASI Score
percent changePlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Percent Change From Baseline in EASI Score-42.69 ± 4.135-60.34 ± 4.018-56.05 ± 2.755-63.31 ± 3.922
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.002 · Mean difference (final values): -17.65 · 95% CI -28.71 to -6.58
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.006 · Mean difference (final values): -13.35 · 95% CI -22.83 to -3.87
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.0002 · Mean difference (final values): -20.62 · 95% CI -31.54 to -9.70
SecondaryPercentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)

The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3)oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with a visual analogue scales (VAS) where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. The SCORAD75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the SCORAD score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)
percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)1.1 (0.2 to 5.8)6.5 (3.0 to 13.4)8.1 (5.0 to 12.9)6.5 (3.0 to 13.5)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.115 · Odds ratio (or): 4.14 · 95% CI 0.71 to 24.29
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.037 · Odds ratio (or): 5.85 · 95% CI 1.11 to 30.88
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.083 · Odds ratio (or): 4.78 · 95% CI 0.81 to 28.08
SecondaryPercentage of Participants Achieving a 4-Point Improvement in Itch Numeric Rating Scale (NRS)

The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 4-Point Improvement in Itch Numeric Rating Scale (NRS)
percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving a 4-Point Improvement in Itch Numeric Rating Scale (NRS)8.2 (4.0 to 16.0)23.1 (15.1 to 33.6)22.9 (17.2 to 29.9)38.2 (28.1 to 49.4)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.012 · Odds ratio (or): 3.28 · 95% CI 1.29 to 8.32
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.002 · Odds ratio (or): 3.71 · 95% CI 1.59 to 8.66
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.00002 · Odds ratio (or): 6.85 · 95% CI 2.79 to 16.82
SecondaryChange From Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS)

The ADSS is a 3-item, participant-administered questionnaire developed to assess the impact of itch on sleep including difficulty falling asleep due to itch, frequency of waking due to itch, and difficulty getting back to sleep last night due to itch. Item 2 frequency of waking last night is reported by selecting the number of times they woke up each night, ranging from 0 to 29 times, where the higher a number indicates a worse outcome. The ADSS is designed to be completed daily, using a daily diary, with respondents thinking about sleep "last night." Each item is scored individually. LS Mean were calculated using an MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS)
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Change From Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS)-0.63 ± 0.149-1.05 ± 0.142-0.85 ± 0.099-1.42 ± 0.140
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.039 · Mean difference (final values): -0.42 · 95% CI -0.82 to -0.02
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.23 · Mean difference (final values): -0.21 · 95% CI -0.56 to 0.13
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.0001 · Mean difference (final values): -0.79 · 95% CI -1.18 to -0.39
SecondaryChange From Baseline in Skin Pain NRS

Skin Pain NRS is a participant-administered,11-point horizontal scale anchored at 0 and 10, with 0 representing "no pain" and 10 representing "worst pain imaginable." Overall severity of a participant's skin pain is indicated by selecting the number, using a daily diary, that best describes the worst level of skin pain in the past 24 hours. LS Mean were calculated using MMRM model includes treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Skin Pain NRS
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Change From Baseline in Skin Pain NRS-1.56 ± 0.284-2.27 ± 0.274-2.40 ± 0.193-3.02 ± 0.271
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.0714 · Mean difference (final values): -0.70 · 95% CI -1.47 to 0.06
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.0134 · Mean difference (final values): -0.84 · 95% CI -1.50 to -0.17
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.0002 · Mean difference (final values): -1.45 · 95% CI -2.21 to -0.69
SecondaryPercentage of Participants Achieving IGA of 0 or 1 With a >=2-point Improvement

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving IGA of 0 or 1 With a >=2-point Improvement
percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving IGA of 0 or 1 With a >=2-point Improvement12.9 (7.5 to 21.2)20.4 (13.5 to 29.7)18.9 (13.9 to 25.2)13.0 (7.6 to 21.4)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.183 · Odds ratio (or): 1.71 · 95% CI 0.78 to 3.75
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.235 · Odds ratio (or): 1.54 · 95% CI 0.76 to 3.11
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.991 · Odds ratio (or): 1.01 · 95% CI 0.43 to 2.36
SecondaryPercentage of Participants Achieving EASI50

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI50 is defined as a ≥ 50% improvement from baseline in the EASI score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving EASI50
percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving EASI5035.5 (26.5 to 45.6)45.2 (35.4 to 55.3)51.4 (44.2 to 58.5)52.2 (42.1 to 62.1)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.263 · Odds ratio (or): 1.41 · 95% CI 0.77 to 2.57
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.016 · Odds ratio (or): 1.89 · 95% CI 1.13 to 3.19
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.031 · Odds ratio (or): 1.93 · 95% CI 1.06 to 3.52
SecondaryPercentage of Participants Achieving EASI75

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving EASI75
percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving EASI7517.2 (10.9 to 26.1)30.1 (21.7 to 40.1)27.6 (21.6 to 34.4)25.0 (17.3 to 34.7)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.058 · Odds ratio (or): 1.97 · 95% CI 0.98 to 3.96
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.072 · Odds ratio (or): 1.77 · 95% CI 0.95 to 3.32
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.224 · Odds ratio (or): 1.56 · 95% CI 0.76 to 3.18
SecondaryPercentage of Participants Achieving IGA of 0

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving IGA of 0
percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving IGA of 00.00 (0.0 to 4.0)2.2 (0.6 to 7.5)1.1 (0.3 to 3.9)3.3 (1.1 to 9.2)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.265 · Odds ratio (or): 5.03 · 95% CI 0.29 to 86.08
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.520 · Odds ratio (or): 2.54 · 95% CI 0.15 to 43.09
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.164 · Odds ratio (or): 7.17 · 95% CI 0.45 to 99.99
SecondaryChange From Baseline in SCORAD

The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. LS Mean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in SCORAD
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Change From Baseline in SCORAD-21.98 ± 2.171-28.06 ± 2.097-28.54 ± 1.438-31.74 ± 2.052
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.040 · Mean difference (final values): -6.08 · 95% CI -11.88 to -0.29
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.010 · Mean difference (final values): -6.56 · 95% CI -11.54 to -1.58
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -9.77 · 95% CI -15.51 to -4.03
SecondaryPercentage of Participants Achieving SCORAD90

The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3)oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with a visual analogue scales (VAS) where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. The SCORAD90 responder is defined as a participant who achieves a ≥ 90% improvement from baseline in the SCORAD score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SCORAD90
percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving SCORAD900.00 (0.0 to 4.0)2.2 (0.6 to 7.5)1.1 (0.3 to 3.9)2.2 (0.6 to 7.6)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.265 · Odds ratio (or): 4.75 · 95% CI 0.31 to 73.93
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.511 · Odds ratio (or): 2.50 · 95% CI 0.16 to 38.40
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.253 · Odds ratio (or): 4.95 · 95% CI 0.32 to 77.11
SecondaryChange From Baseline in Body Surface Area (BSA) Affected

The BSA affected by AD will be assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage will be reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Use the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSAhead and neck + 0.3\*BSAtrunk + 0.2\* BSAupper limbs + 0.4\*BSAlower limbs. LS Mean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Body Surface Area (BSA) Affected
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Change From Baseline in Body Surface Area (BSA) Affected-19.76 ± 2.257-25.98 ± 2.178-25.26 ± 1.488-28.17 ± 2.125
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.044 · Mean difference (final values): -6.21 · 95% CI -12.26 to -0.16
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.037 · Mean difference (final values): -5.50 · 95% CI -10.67 to -0.32
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.006 · Mean difference (final values): -8.41 · 95% CI -14.37 to -2.45
SecondaryPercentage of Participants Developing Skin Infections Requiring Antibiotic Treatment

Percentage of participants developing skin infections requiring antibiotic treatment.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Developing Skin Infections Requiring Antibiotic Treatment
percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Developing Skin Infections Requiring Antibiotic Treatment5.46.56.55.4
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Fisher Exact · p = >.999
  • Placebo vs 2 mg Baricitinib · Fisher Exact · p = 0.797
  • Placebo vs 4 mg Baricitinib · Fisher Exact · p = >.999
SecondaryMean Number of Days Without Topical Corticosteroids (TCS) Use

The ANCOVA model includes treatment, region, and baseline disease severity (IGA) as factors.

Time frame:
Week 16
Reported as:
Least squares mean · days
Mean Number of Days Without Topical Corticosteroids (TCS) Use
daysPlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Mean Number of Days Without Topical Corticosteroids (TCS) Use12.18 ± 3.3920.80 ± 3.3717.65 ± 2.5319.43 ± 3.41
Statistical analysis
  • Placebo vs 1 mg Baricitinib · ANCOVA · p = 0.056 · Mean difference (final values): 8.62 · 95% CI -0.22 to 17.45
  • Placebo vs 2 mg Baricitinib · ANCOVA · p = 0.164 · Mean difference (final values): 5.48 · 95% CI -2.24 to 13.19
  • Placebo vs 4 mg Baricitinib · ANCOVA · p = 0.110 · Mean difference (final values): 7.25 · 95% CI -1.66 to 16.15
SecondaryMean Gram Quantity of Low and Moderate Potency Background Topical Corticosteroid (TCS) Used (Tube Weights)

Average weights of full tubes were used to determine the dispensed weights for each region. Returned tubes were weighed with cap without carton to determine the amount of TCS in grams (g) used at each visit. Analysis was done via analysis of variance (ANOVA), with geographic region, baseline disease severity, and treatment as factors in the model.

Time frame:
Week 16
Reported as:
Least squares mean · grams
Mean Gram Quantity of Low and Moderate Potency Background Topical Corticosteroid (TCS) Used (Tube Weights)
gramsPlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Mean Gram Quantity of Low and Moderate Potency Background Topical Corticosteroid (TCS) Used (Tube Weights)242.59 ± 27.60194.53 ± 27.42185.70 ± 20.67171.17 ± 27.16
Statistical analysis
  • Placebo vs 1 mg Baricitinib · ANOVA · p = 0.178 · Mean difference (final values): -48.06 · 95% CI -118.00 to 21.88
  • Placebo vs 2 mg Baricitinib · ANOVA · p = 0.066 · Mean difference (final values): -56.90 · 95% CI -117.56 to 3.77
  • Placebo vs 4 mg Baricitinib · ANOVA · p = 0.045 · Mean difference (final values): -71.42 · 95% CI -141.24 to -1.60
SecondaryPercent Change From Baseline in Itch NRS

The Itch NRS is a participant-administered, 11-point horizontal scale, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours. LS Means were calculated using MMRM model with treatment, region, baseline disease severity, visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Itch NRS
percent changePlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Percent Change From Baseline in Itch NRS-17.48 ± 4.835-28.80 ± 4.663-32.89 ± 3.258-37.24 ± 4.609
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.088 · Mean difference (final values): -11.32 · 95% CI -24.33 to 1.70
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.007 · Mean difference (final values): -15.41 · 95% CI -26.67 to -4.16
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.003 · Mean difference (final values): -19.76 · 95% CI -32.71 to -6.82
SecondaryPercent Change From Baseline in Itch NRS at Week 24

The Itch NRS is a participant-administered, 11-point horizontal scale, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours. LS Means were calculated using MMRM model with treatment, region, baseline disease severity, visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-interaction as fixed continuous effects.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Percent Change From Baseline in Itch NRS at Week 24
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Percent Change From Baseline in Itch NRS at Week 24-15.35 ± 5.349-29.35 ± 5.039-30.11 ± 3.495-33.16 ± 4.972
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.055 · Mean difference (final values): -14.00 · 95% CI -28.28 to 0.28
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.020 · Mean difference (final values): -14.76 · 95% CI -27.15 to -2.38
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.014 · Mean difference (final values): -17.82 · 95% CI -32.01 to -3.62
SecondaryChange From Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM)

The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life. LS Mean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by visit-interactions as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM)
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Change From Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM)-4.18 ± 0.907-6.24 ± 0.872-7.27 ± 0.602-9.27 ± 0.855
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.095 · Mean difference (final values): -2.06 · 95% CI -4.47 to -0.36
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.004 · Mean difference (final values): -3.09 · 95% CI -5.16 to -1.01
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -5.09 · 95% CI -7.48 to -2.70
SecondaryChange From Baseline in the Patient Global Impression of Severity - Atopic Dermatitis (PGI-S-AD) Score

The PGI-S-AD is a single-item question asking the participant how they would rate their overall AD symptoms over the past 24 hours, using a daily diary. The 5 categories of responses are "(0) no symptoms", "(1) very mild", "(2) mild" "(3) moderate", and "(4) severe." LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Patient Global Impression of Severity - Atopic Dermatitis (PGI-S-AD) Score
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Change From Baseline in the Patient Global Impression of Severity - Atopic Dermatitis (PGI-S-AD) Score-0.49 ± 0.107-0.74 ± 0.103-0.77 ± 0.072-1.07 ± 0.101
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.097 · Mean difference (final values): -0.24 · 95% CI -0.53 to 0.04
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.033 · Mean difference (final values): -0.27 · 95% CI -0.52 to -0.02
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.58 · 95% CI -0.86 to -0.29
SecondaryChange From Baseline on the Hospital Anxiety Depression Scale (HADS)

The HADS is a participant-rated instrument used to assess both anxiety and depression. This instrument consists of 14 item questionnaire, each item is rated on a 4-point scale, giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale are considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7, 'normal.' LS Mean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline on the Hospital Anxiety Depression Scale (HADS)
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Anxiety-0.48 ± 0.382-1.04 ± 0.366-1.59 ± 0.256-1.32 ± 0.362
Depression-0.40 ± 0.383-0.69 ± 0.367-1.03 ± 0.256-1.57 ± 0.362
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.272 · Mean difference (final values): -0.57 · 95% CI -1.58 to 0.45
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.013 · Mean difference (final values): -1.12 · 95% CI -1.99 to -0.24
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.099 · Mean difference (final values): -0.85 · 95% CI -1.85 to 0.16
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.584 · Mean difference (final values): -0.28 · 95% CI -1.30 to 0.74
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.162 · Mean difference (final values): -0.63 · 95% CI -1.51 to 0.25
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.024 · Mean difference (final values): -1.17 · 95% CI -2.18 to -0.15
SecondaryChange From Baseline in the Dermatology Life Quality Index (DLQI)

The DLQI is a simple, participant-administered,10 question, validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period of this scale is over the last "week." Response categories include "not at all," "a little," "a lot," and "very much," with corresponding scores of 0, 1, 2, and 3, respectively, and unanswered or "not relevant" responses scored as "0." Scores range from 0 to 30 ("no impact on participant's life" to "extremely large effect on participant's life"), and a 4-point change from baseline is considered as the minimal clinically important difference threshold. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Dermatology Life Quality Index (DLQI)
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Change From Baseline in the Dermatology Life Quality Index (DLQI)-4.95 ± 0.752-6.18 ± 0.719-6.57 ± 0.494-7.95 ± 0.705
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.228 · Mean difference (final values): -1.23 · 95% CI -3.23 to 0.77
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.065 · Mean difference (final values): -1.62 · 95% CI -3.35 to 0.10
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.003 · Mean difference (final values): -3.01 · 95% CI -4.99 to -1.02
SecondaryChange From Baseline on the Work Productivity and Activity Impairment - Atopic Dermatitis (WPAI-AD) Questionnaire

The WPAI-AD participant questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. The WPAI-AD consists of 6 items grouped in 4 domains: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment, that range from 0% to 100%, with higher values indicating greater impairment. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline on the Work Productivity and Activity Impairment - Atopic Dermatitis (WPAI-AD) Questionnaire
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Absenteeism-4.77 ± 2.365-5.69 ± 2.433-2.98 ± 1.639-4.56 ± 2.258
Presenteeism-14.86 ± 3.182-11.80 ± 3.161-14.56 ± 2.133-14.81 ± 3.000
Work Productivity Loss-13.22 ± 3.560-12.07 ± 3.565-13.07 ± 2.440-14.12 ± 3.396
Activity Impairment-16.46 ± 2.853-18.46 ± 2.729-20.86 ± 1.847-23.92 ± 2.660
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.784 · Mean difference (final values): -0.92 · 95% CI -7.50 to 5.67
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.525 · Mean difference (final values): 1.79 · 95% CI -3.75 to 7.34
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.947 · Mean difference (final values): 0.21 · 95% CI -6.11 to 6.53
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.488 · Mean difference (final values): 3.06 · 95% CI -5.62 to 11.74
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.936 · Mean difference (final values): 0.30 · 95% CI -7.02 to 7.62
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.991 · Mean difference (final values): 0.05 · 95% CI -8.35 to 8.45
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.816 · Mean difference (final values): 1.15 · 95% CI -8.57 to 10.88
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.971 · Mean difference (final values): 0.15 · 95% CI -8.08 to 8.38
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.852 · Mean difference (final values): -0.90 · 95% CI -10.36 to 8.56
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.607 · Mean difference (final values): -1.99 · 95% CI -9.61 to 5.63
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.186 · Mean difference (final values): -4.40 · 95% CI -10.92 to 2.12
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.052 · Mean difference (final values): -7.45 · 95% CI -14.96 to 0.06
SecondaryChange From Baseline in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Index Score United States and United Kingdom Algorithm

The EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1, with higher score indicating better health state. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Index Score United States and United Kingdom Algorithm
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
US Health State Index0.04 ± 0.0160.08 ± 0.0160.09 ± 0.0110.11 ± 0.015
UK Health State Index0.06 ± 0.0230.11 ± 0.0220.13 ± 0.0160.15 ± 0.022
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.131 · Mean difference (final values): 0.03 · 95% CI -0.01 to 0.08
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.017 · Mean difference (final values): 0.05 · 95% CI 0.01 to 0.08
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.003 · Mean difference (final values): 0.06 · 95% CI 0.02 to 0.11
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.102 · Mean difference (final values): 0.05 · 95% CI -0.01 to 0.11
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.014 · Mean difference (final values): 0.07 · 95% CI 0.01 to 0.12
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.003 · Mean difference (final values): 0.09 · 95% CI 0.03 to 0.15
SecondaryChange From Baseline on the European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Visual Analog Score (VAS)

EQ-5D-5L is a 2-part measurement. The second part is assessed using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine. LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interactions as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · millimeters (mm)
Change From Baseline on the European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Visual Analog Score (VAS)
millimeters (mm)Placebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Change From Baseline on the European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Visual Analog Score (VAS)7.64 ± 2.40711.63 ± 2.3068.76 ± 1.58811.03 ± 2.260
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.221 · Mean difference (final values): 3.99 · 95% CI -2.41 to 10.39
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.689 · Mean difference (final values): 1.12 · 95% CI -4.40 to 6.65
  • Placebo vs 4 mg Baricitinib · Mixed Models Analysis · p = 0.294 · Mean difference (final values): 3.39 · 95% CI -2.95 to 9.74
SecondaryPercentage of Participants Achieving EASI75

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving EASI75
Percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Percentage of Participants Achieving EASI7526.9 (18.9 to 36.7)33.3 (24.6 to 43.4)30.3 (24.1 to 37.2)37.0 (27.8 to 47.2)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.382 · Odds ratio (or): 1.33 · 95% CI 0.70 to 2.54
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.638 · Odds ratio (or): 1.15 · 95% CI 0.65 to 2.02
  • Placebo vs 4 mg Baricitinib · Regression, Logistic · p = 0.169 · Odds ratio (or): 1.56 · 95% CI 0.83 to 2.96
SecondaryPercent Change From Baseline in Itch NRS at Week 52

The Itch NRS is a participant-administered, 11-point horizontal scale, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours. LS Means were calculated using MMRM model with treatment, region, baseline disease severity, visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-interaction as fixed continuous effects.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Itch NRS at Week 52
Percent ChangePlacebo1 mg Baricitinib2 mg Baricitinib4 mg Baricitinib
Percent Change From Baseline in Itch NRS at Week 52-12.13 ± 7.075-19.49 ± 6.679-16.01 ± 4.729-29.31 ± 6.619
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Linear · p = 0.447 · Ls mean difference (final values): -7.36 · 95% CI -26.38 to 11.66
  • Placebo vs 2 mg Baricitinib · Regression, Linear · p = 0.646 · Ls mean difference (final values): -3.88 · 95% CI -20.50 to 12.74
  • Placebo vs 4 mg Baricitinib · Regression, Linear · p = 0.075 · Ls mean difference (final values): -17.18 · 95% CI -36.14 to 1.77
SecondaryPercentage of Participants With a Response of IGA 0, 1, or 2 Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (All Participants Entering the Substudy)

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using modified last observation carried forward (mLOCF).

Time frame:
Week 68
Reported as:
Number · Percentage of participants
Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (All Participants Entering the Substudy)
Percentage of participantsLTE Substudy 4 mg Baricitinib to 4 mg Baricitinib (Responders/Partial Responders)LTE Substudy 4 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 1 mg Baricitinib (Responders/Partial Responders)
Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (All Participants Entering the Substudy)93.8 (71.7 to 98.9)56.3 (33.2 to 76.9)84.0 (65.3 to 93.6)50.0 (31.4 to 68.6)
SecondaryPercentage of Participants With a Response of IGA 0, 1, or 2 Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (All Participants Entering the Substudy)

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using modified last observation carried forward (mLOCF).

Time frame:
Week 104
Reported as:
Number · Percentage of participants
Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (All Participants Entering the Substudy)
Percentage of participantsLTE Substudy 4 mg Baricitinib to 4 mg Baricitinib (Responders/Partial Responders)LTE Substudy 4 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 1 mg Baricitinib (Responders/Partial Responders)
Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (All Participants Entering the Substudy)68.8 (44.4 to 85.8)50.0 (28.0 to 72.0)72.0 (52.4 to 85.7)25.0 (12.0 to 44.9)
SecondaryPercentage of Participants With a Response of IGA 0, 1 Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (All Participants Entering the Substudy)

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

Time frame:
Week 68
Reported as:
Number · Percentage of participants
Percentage of Participants With a Response of IGA 0, 1 Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (All Participants Entering the Substudy)
Percentage of participantsLTE Substudy 4mg Baricitinib to 4mg Baricitinib (Responders/Partial Responders)LTE Substudy 4 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 1 mg Baricitinib (Responders/Partial Responders)
Percentage of Participants With a Response of IGA 0, 1 Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (All Participants Entering the Substudy)50 (28.0 to 72.0)25.0 (10.2 to 49.5)44.0 (26.7 to 62.9)20.8 (9.2 to 40.5)
SecondaryPercentage of Participants With a Response of IGA 0, 1 Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (All Participants Entering the Substudy)

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

Time frame:
Week 104
Reported as:
Number · Percentage of participants
Percentage of Participants With a Response of IGA 0, 1 Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (All Participants Entering the Substudy)
Percentage of participantsLTE Substudy 4mg Baricitinib to 4mg Baricitinib (Responders/Partial Responders)LTE Substudy 4 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 1 mg Baricitinib (Responders/Partial Responders)
Percentage of Participants With a Response of IGA 0, 1 Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (All Participants Entering the Substudy)43.8 (23.1 to 66.8)25.0 (10.2 to 49.5)44.0 (26.7 to 62.9)8.3 (2.3 to 25.8)
SecondaryPercentage of Participants With a Response of EASI75 From Baseline Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (All Participants Entering the Substudy)

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

Time frame:
Week 68
Reported as:
Number · Percentage of participants
Percentage of Participants With a Response of EASI75 From Baseline Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (All Participants Entering the Substudy)
Percentage of participantsLTE Substudy 4mg Baricitinib to 4mg Baricitinib (Responders/Partial Responders)LTE Substudy 4 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 1 mg Baricitinib (Responders/Partial Responders)
Percentage of Participants With a Response of EASI75 From Baseline Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (All Participants Entering the Substudy)75.0 (50.5 to 89.8)56.3 (33.2 to 76.90)72.0 (52.4 to 85.7)41.7 (24.5 to 61.2)
SecondaryPercentage of Participants With a Response of EASI75 From Baseline Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (All Participants Entering the Substudy)

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

Time frame:
Week 104
Reported as:
Number · Percentage of participants
Percentage of Participants With a Response of EASI75 From Baseline Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (All Participants Entering the Substudy)
Percentage of participantsLTE Substudy 4mg Baricitinib to 4mg Baricitinib (Responders/Partial Responders)LTE Substudy 4 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 1 mg Baricitinib (Responders/Partial Responders)
Percentage of Participants With a Response of EASI75 From Baseline Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (All Participants Entering the Substudy)68.8 (44.4 to 85.8)56.3 (33.2 to 76.9)56.0 (37.1 to 73.3)33.3 (18.0 to 53.3)
SecondaryPercentage of Participants With a Response of IGA 0, 1, or 2 Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (Participants Entering the Substudy With IGA 0 or 1)

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using modified last observation carried forward (mLOCF).

Time frame:
Week 68
Reported as:
Number · Percentage of participants
Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (Participants Entering the Substudy With IGA 0 or 1)
Percentage of participantsLTE Substudy 4mg Baricitinib to 4mg Baricitinib(Responders/Partial Responders)LTE Substudy 4 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 1 mg Baricitinib (Responders/Partial Responders)
Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (Participants Entering the Substudy With IGA 0 or 1)100 (72.2 to 100)77.8 (45.3 to 93.7)100 (72.2 to 100)55.6 (26.7 to 81.1)
SecondaryPercentage of Participants With a Response of IGA 0, 1, or 2 Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (Participants Entering the Substudy With IGA 0 or 1)

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using mLOCF.

Time frame:
Week 104
Reported as:
Number · Percentage of participants
Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (Participants Entering the Substudy With IGA 0 or 1)
Percentage of participantsLTE Substudy 4 mg Baricitinib to 4 mg Baricitinib (Responders/Partial Responders)LTE Substudy 4 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 1 mg Baricitinib (Responders/Partial Responders)
Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (Participants Entering the Substudy With IGA 0 or 1)80.0 (49.0 to 94.3)66.7 (35.4 to 87.9)100 (72.2 to 100)33.3 (12.1 to 64.6)
SecondaryPercentage of Participants With a Response of IGA 0 or 1 Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (Participants Entering the Substudy With IGA 0 or 1)

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using mLOCF.

Time frame:
Week 68
Reported as:
Number · Percentage of participants
Percentage of Participants With a Response of IGA 0 or 1 Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (Participants Entering the Substudy With IGA 0 or 1)
Percentage of participantsLTE Substudy 4 mg Baricitinib to 4 mg Baricitinib (Responders/Partial Responders)LTE Substudy 4 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 1 mg Baricitinib (Responders/Partial Responders)
Percentage of Participants With a Response of IGA 0 or 1 Assessed at 16 Weeks After Rerandomization (Week 68) Randomized Downtitration (Participants Entering the Substudy With IGA 0 or 1)60.0 (31.3 to 83.2)33.3 (12.1 to 64.6)90.0 (59.6 to 98.2)55.6 (26.7 to 81.1)
SecondaryPercentage of Participants With a Response of IGA 0, 1 Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (Participants Entering the Substudy With IGA 0 or 1)

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using mLOCF.

Time frame:
Week 104
Reported as:
Number · Percentage of participants
Percentage of Participants With a Response of IGA 0, 1 Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (Participants Entering the Substudy With IGA 0 or 1)
Percentage of participantsLTE Substudy 4 mg Baricitinib to 4 mg Baricitinib (Responders/Partial Responders)LTE Substudy 4 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 1 mg Baricitinib (Responders/Partial Responders)
Percentage of Participants With a Response of IGA 0, 1 Assessed at 16 Weeks After Rerandomization (Week 104) Randomized Downtitration (Participants Entering the Substudy With IGA 0 or 1)50.0 (23.7 to 76.3)33.3 (12.1 to 64.6)90.0 (59.6 to 98.2)22.2 (6.3 to 54.7)
SecondaryPercentage of Participants With a Response of IGA 0, 1, or 2 Assessed at Week 68 Participants Not Entered Into Substudy (All Participants)

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using mLOCF.

Time frame:
Week 68
Reported as:
Number · Percentage of participants
Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at Week 68 Participants Not Entered Into Substudy (All Participants)
Percentage of participantsLTE 4 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 2 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 1 mg Baricitinib (Responders/ Partial Responders) - Did Not Enter SubstudyLTE Placebo (Responders/Partial Responders) - Did Not Enter Substudy
Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at Week 68 Participants Not Entered Into Substudy (All Participants)100 (64.6 to 100)86.4 (66.7 to 95.3)100 (89.8 to 100)93.1 (78.0 to 98.1)
SecondaryPercentage of Participants With a Response of IGA 0, 1, or 2 Assessed at Week 104 Participants Not Entered Into Substudy (All Participants)

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using mLOCF.

Time frame:
Week 104
Reported as:
Number · Percentage of participants
Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at Week 104 Participants Not Entered Into Substudy (All Participants)
Percentage of participantsLTE 4 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 2 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 1 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE Placebo (Responders/Partial Responders) - Did Not Enter Substudy
Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at Week 104 Participants Not Entered Into Substudy (All Participants)100 (64.6 to 100)86.4 (66.7 to 95.3)97.1 (85.1 to 99.5)93.1 (78.0 to 98.1)
SecondaryPercentage of Participants With a Response of IGA 0 or 1 Assessed at Week 68 - Participants Not Entered Into Substudy (All Participants)

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using mLOCF.

Time frame:
Week 68
Reported as:
Number · Percentage of participants
Percentage of Participants With a Response of IGA 0 or 1 Assessed at Week 68 - Participants Not Entered Into Substudy (All Participants)
Percentage of participantsLTE 4 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 2 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 1 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE Placebo (Responders/Partial Responders) - Did Not Enter Substudy
Percentage of Participants With a Response of IGA 0 or 1 Assessed at Week 68 - Participants Not Entered Into Substudy (All Participants)14.3 (2.6 to 51.3)50.0 (30.7 to 69.3)47.1 (31.5 to 63.3)51.7 (34.4 to 68.6)
SecondaryPercentage of Participants With a Response of IGA 0 or 1 Assessed at Week 104 - Participants Not Entered Into Substudy (All Participants)

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using mLOCF.

Time frame:
Week 104
Reported as:
Number · Percentage of participants
Percentage of Participants With a Response of IGA 0 or 1 Assessed at Week 104 - Participants Not Entered Into Substudy (All Participants)
Percentage of participantsLTE 4 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 2 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 1 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE Placebo (Responders/Partial Responders) - Did Not Enter Substudy
Percentage of Participants With a Response of IGA 0 or 1 Assessed at Week 104 - Participants Not Entered Into Substudy (All Participants)42.9 (15.8 to 75.0)50.0 (30.7 to 69.3)47.1 (31.5 to 63.3)48.3 (31.4 to 65.6)
SecondaryPercentage of Participants With A Response of EASI75 Assessed at Week 68 - Participants Not Entered Into Substudy (All Participants)

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

Time frame:
Week 68
Reported as:
Number · Percentage of participants
Percentage of Participants With A Response of EASI75 Assessed at Week 68 - Participants Not Entered Into Substudy (All Participants)
Percentage of participantsLTE 4 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 2 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 1 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE Placebo (Responders/Partial Responders) - Did Not Enter Substudy
Percentage of Participants With A Response of EASI75 Assessed at Week 68 - Participants Not Entered Into Substudy (All Participants)57.1 (25.0 to 84.2)63.6 (43.0 to 80.3)76.5 (60.0 to 87.6)62.1 (44.0 to 77.3)
SecondaryPercentage of Participants With A Response of EASI75 Assessed at Week 104 - Participants Not Entered Into Substudy (All Participants)

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

Time frame:
Week 104
Reported as:
Number · Percentage of participants
Percentage of Participants With A Response of EASI75 Assessed at Week 104 - Participants Not Entered Into Substudy (All Participants)
Percentage of participantsLTE 4 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 2 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 1 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE Placebo (Responders/Partial Responders) - Did Not Enter Substudy
Percentage of Participants With A Response of EASI75 Assessed at Week 104 - Participants Not Entered Into Substudy (All Participants)85.7 (48.7 to 97.4)68.2 (47.3 to 83.6)70.6 (53.8 to 83.2)72.4 (54.3 to 85.3)
SecondaryTime to Retreatment (Time to IGA ≥3) Randomized Downtitration (All Patients Entering the Substudy)

Participants who entered the Substudy and relapsed with an IGA ≥3.

Time frame:
Week 52 Up to Week 200
Reported as:
Median · Days
Time to Retreatment (Time to IGA ≥3) Randomized Downtitration (All Patients Entering the Substudy)
Days4 mg Baricitinib to 4 mg Baricitinib to 4 mg Baricitinib4 mg Baricitinib to 2 mg Baricitinib to 4 mg Baricitinib2 mg Baricitinib to 2 mg Baricitinib to 2 mg Baricitinib2 mg Baricitinib to 1 mg Baricitinib to 2 mg Baricitinib
Time to Retreatment (Time to IGA ≥3) Randomized Downtitration (All Patients Entering the Substudy)218 (29 to NA)79 (28 to 359)68 (28 to 364)71 (29 to 225)

Adverse events

Collected over Baseline up to Week 200. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/93 (0%)5/93 (5.4%)50/93 (53.8%)
1 mg Baricitinib0/93 (0%)7/93 (7.5%)63/93 (67.7%)
2 mg Baricitinib0/185 (0%)9/184 (4.9%)130/184 (70.7%)
4 mg Baricitinib0/92 (0%)10/92 (10.9%)75/92 (81.5%)
Long Term Extension(LTE) Substudy 2mg Baricitinib to 1mg Baricitinib (Responders/Partial Responders)0/24 (0%)3/24 (12.5%)17/24 (70.8%)
LTE Substudy 2 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)0/25 (0%)4/25 (16%)16/25 (64%)
LTE Substudy 4 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)0/16 (0%)3/16 (18.8%)13/16 (81.3%)
LTE Substudy 4 mg Baricitinib to 4 mg Baricitinib (Responders/Partial Responders)0/16 (0%)3/16 (18.8%)16/16 (100%)
LTE Placebo (Responders/Partial Responders) - Did Not Enter Substudy0/29 (0%)1/29 (3.4%)16/29 (55.2%)
LTE 1 mg Baricitinib (Responders/Partial Responders) - Did Not Enter Substudy0/34 (0%)1/34 (2.9%)25/34 (73.5%)
LTE 2 mg Baricitinib (Responders/Partial Responders) - Did Not Enter Substudy0/22 (0%)1/22 (4.5%)16/22 (72.7%)
LTE 4 mg Baricitinib (Responders/Partial Responders) - Did Not Enter Substudy0/7 (0%)2/7 (28.6%)7/7 (100%)
LTE Placebo to 2 mg Baricitinib (Non-responders) - Did Not Enter Substudy0/11 (0%)1/11 (9.1%)6/11 (54.5%)
LTE Placebo to 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy0/12 (0%)2/12 (16.7%)10/12 (83.3%)
LTE 1 mg Baricitinib to 2 mg Baricitinib (Non-responders) - Did Not Enter Substudy0/13 (0%)2/13 (15.4%)11/13 (84.6%)
LTE 1 mg Baricitinib to 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy0/14 (0%)3/14 (21.4%)13/14 (92.9%)
LTE 2 mg Baricitinib to 2 mg Baricitinib (Non-responders) - Did Not Enter Substudy0/27 (0%)3/27 (11.1%)18/27 (66.7%)
LTE 2 mg Baricitinib to 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy0/26 (0%)5/26 (19.2%)18/26 (69.2%)
LTE 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy0/24 (0%)4/24 (16.7%)16/24 (66.7%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventPlacebo1 mg Baricitinib2 mg Baricitinib4 mg BaricitinibLong Term Extension(LTE) Substudy 2mg Baricitinib to 1mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 4 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 4 mg Baricitinib to 4 mg Baricitinib (Responders/Partial Responders)LTE Placebo (Responders/Partial Responders) - Did Not Enter SubstudyLTE 1 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 2 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 4 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE Placebo to 2 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE Placebo to 4 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE 1 mg Baricitinib to 2 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE 1 mg Baricitinib to 4 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE 2 mg Baricitinib to 2 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE 2 mg Baricitinib to 4 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy
CellulitisInfections and infestations1/930/931/1840/920/240/250/160/160/290/340/221/70/110/120/130/140/271/260/24
PeritonitisInfections and infestations0/930/930/1840/920/240/250/160/160/290/340/221/70/110/120/130/140/270/260/24
TenosynovitisMusculoskeletal and connective tissue disorders0/930/930/1840/920/240/250/160/160/290/340/221/70/110/120/130/140/270/260/24
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/490/580/1320/570/210/200/100/80/150/210/140/30/40/90/91/80/200/200/17
Covid-19Infections and infestations0/930/930/1840/920/240/250/160/161/290/340/220/71/110/120/130/141/270/260/24
ErysipelasInfections and infestations1/930/930/1841/920/240/251/161/160/290/340/220/70/111/120/130/140/270/260/24
PerichondritisInfections and infestations0/930/930/1840/920/240/250/160/160/290/340/220/70/111/120/130/140/270/260/24
PneumoniaInfections and infestations0/930/931/1840/920/240/250/160/160/290/340/220/70/111/120/130/140/270/260/24
Retinal detachmentEye disorders0/930/930/1840/920/240/250/160/160/290/340/220/70/110/121/130/140/270/260/24
Injury cornealInjury, poisoning and procedural complications0/930/930/1840/920/240/250/160/160/290/340/220/70/110/121/130/140/270/260/24
Most frequent other events
Showing 10 of 193
Most frequent other events
EventPlacebo1 mg Baricitinib2 mg Baricitinib4 mg BaricitinibLong Term Extension(LTE) Substudy 2mg Baricitinib to 1mg Baricitinib (Responders/Partial Responders)LTE Substudy 2 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 4 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)LTE Substudy 4 mg Baricitinib to 4 mg Baricitinib (Responders/Partial Responders)LTE Placebo (Responders/Partial Responders) - Did Not Enter SubstudyLTE 1 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 2 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE 4 mg Baricitinib (Responders/Partial Responders) - Did Not Enter SubstudyLTE Placebo to 2 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE Placebo to 4 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE 1 mg Baricitinib to 2 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE 1 mg Baricitinib to 4 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE 2 mg Baricitinib to 2 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE 2 mg Baricitinib to 4 mg Baricitinib (Non-responders) - Did Not Enter SubstudyLTE 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy
NasopharyngitisInfections and infestations14/9316/9336/18434/928/243/253/163/163/294/345/224/71/116/122/131/143/273/262/24
Covid-19Infections and infestations0/930/930/1840/923/244/251/164/164/296/344/222/71/110/121/133/144/275/264/24
GastroenteritisInfections and infestations0/932/934/1842/920/241/250/160/160/290/340/222/71/110/120/130/140/271/260/24
Oral herpesInfections and infestations6/935/936/1847/921/242/250/161/160/291/343/222/71/111/122/130/140/270/261/24
PharyngitisInfections and infestations4/931/934/1841/920/240/250/160/160/292/340/222/70/110/120/130/140/270/260/24
HypertensionVascular disorders1/933/935/1843/920/241/251/162/162/290/341/222/71/110/121/131/141/270/260/24
Vulvovaginal candidiasisInfections and infestations0/440/352/520/350/31/50/60/80/141/131/81/40/70/30/40/61/70/60/7
DysmenorrhoeaReproductive system and breast disorders0/442/350/520/350/30/50/60/80/143/130/80/40/70/30/40/60/70/61/7
ConjunctivitisInfections and infestations1/931/933/1845/920/240/251/161/160/291/340/220/70/110/120/133/141/270/261/24
HeadacheNervous system disorders8/938/9314/18410/921/245/251/160/161/292/341/221/70/111/120/130/141/272/261/24

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Placebo1 mg Baricitinib2 mg Baricitinib4 mg BaricitinibTotal
Mean38.7 ± 13.638.9 ± 14.037.3 ± 13.638.7 ± 13.338.2 ± 13.6
Sex: Female, Male
Sex: Female, Male(Participants)Placebo1 mg Baricitinib2 mg Baricitinib4 mg BaricitinibTotal
Female44355235166
Male495813357297
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo1 mg Baricitinib2 mg Baricitinib4 mg BaricitinibTotal
Hispanic or Latino1113261464
Not Hispanic or Latino546210155272
Unknown or Not Reported28185823127
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo1 mg Baricitinib2 mg Baricitinib4 mg BaricitinibTotal
American Indian or Alaska Native00000
Asian1619361889
Native Hawaiian or Other Pacific Islander00000
Black or African American332311
White747014571360
More than one race01203
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Placebo1 mg Baricitinib2 mg Baricitinib4 mg BaricitinibTotal
Austria132410
Netherlands309416
Belgium3512626
Finland22217
Poland10915741
Brazil810201048
Italy11913437
France9616839
Germany1518371888
Japan1516321679
Russia525214
Spain7715635
Switzerland01124
United Kingdom456419
08

Study locations

103 sites
  • Universitätsklinikum Graz
    Graz, Steiermark 8036, Austria
  • Universitätsklinik Innsbruck
    Innsbruck, Tyrol 6020, Austria
  • KA Rudolfstiftung
    Wien, 1030, Austria
  • AKH
    Wien, 1090, Austria
  • Sozialmed. Zentrum Ost - Donauspital
    Wien, 1220, Austria
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • Universitair Ziekenhuis Brussel
    Brussel, 1090, Belgium
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • UZ Leuven - Campus Sint-Rafaël
    Leuven, 3000, Belgium
  • Cedoes Centro Diagnostico Pequisa Osteoporose E Santo Ltd
    Vitoria, ES 29055 450, Brazil
  • Irmandade da Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, Rio Grande Do Sul 90020-090, Brazil
  • Hospital Moinhos de Vento - Instituto de Educação e Pesquisa
    Porto Alegre, Rio Grande Do Sul 90560-030, Brazil
  • CCBR Brasil Centro de Analises e Pesquisas Clínicas LTDA
    Rio de Janeiro, RJ 22271-100, Brazil
  • IDERJ - Instituto de Dermatologia e Estética do Brasil
    Rio de Janeiro, RJ 22470-220, Brazil
  • Faculdade de Ciências Médicas - UNICAMP
    Campinas, Sao Paulo 13083-887, Brazil
  • Fundação Faculdade de Medicina do ABC
    Santo André, Sao Paulo 09060-650, Brazil
  • Hospital das Clinicas da FMRP
    Ribeirao Preto, SP 14048-900, Brazil
  • Hospital da Clinicas da Faculdade de Medicina da USP
    Sao Paulo, 05403-000, Brazil
  • Terveystalo Tampere
    Tampere, Irkanmaa 33100, Finland
  • Helsinki University Central Hospital
    Helsinki, 00250, Finland
  • Hospital Mehiläinen Neo
    Turku, 20520, Finland
  • Hôpital de Pontchaillou
    Rennes, Cedex 9 35033, France
  • CHU de Besancon Hopital Jean Minjoz
    Besancon Cedex, 25030, France
  • CHU de Bordeaux Hopital Saint Andre
    Bordeaux Cedex, 33075, France
  • Hôpital C. HURIEZ
    Lille, 59037, France
  • Hôpital Emile Muller
    Mulhouse, 68100, France
  • Chru De Nantes Hotel-Dieu
    Nantes Cedex 1, 44093, France
  • CHU de Nice Hopital de L'Archet
    Nice cedex 3, 06202, France
  • Hopital Sainte Anne (H.I.A)
    Toulon Cedex 9, 83800, France
  • Hopital Larrey
    Toulouse cedex 9, 31059, France
  • Centre Hospitalier de Valence
    Valence, 26953, France
  • Universitätsklinikum Heidelberg
    Heidelberg, Baden-Württemberg 69120, Germany
  • Hautarztpraxis Dr. Leitz und Kollegen
    Stuttgart, Baden-Württemberg 70178, Germany
  • Universitätsklinikum Erlangen
    Erlangen, Bayern 91054, Germany
  • Klinikum Rechts der Isar der TU München
    München, Bayern 80802, Germany
  • Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
    Frankfurt am Main, Hessen 60590, Germany
  • Elbe Kliniken Stade Buxtehude GmbH Klinikum Buxtehude
    Buxtehude, Niedersachsen 21614, Germany
  • Medizinische Hochschule Hannover
    Hannover, Niedersachsen 30449, Germany
  • Klinische Forschung Osnabrück
    Osnabrück, Niedersachsen 49074, Germany
  • Fachklinik Bad Bentheim
    Bad Bentheim, Nordrhein-Westfalen 48455, Germany
  • St Josef-Hospital Bochum
    Bochum, Nordrhein-Westfalen 44791, Germany
  • Universitätsklinikum Bonn
    Bonn, Nordrhein-Westfalen 53127, Germany
  • Universitaetsklinikum Essen
    Essen, Nordrhein-Westfalen 45147, Germany
  • Universitätsklinikum Münster
    Münster, Nordrhein-Westfalen 48149, Germany
  • Universitatsmedizin der Johannes Gutenberg-Universitat Mainz
    Mainz, Rheinland-Pfalz 55131, Germany
  • Universitätsklinikum Jena
    Jena, Thüringen 07743, Germany
  • Charité Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • Universitätsklinikum Hamburg - Eppendorf
    Hamburg, 20246, Germany
  • Fondazione IRCCS Osp.Maggiore Policlinico - Dermatologia
    Milano, Milan 20122, Italy
  • Ospedale Clinicizzato San Donato
    San Donato Milanese, Milan 20097, Italy
  • Dip.to Med. Sperimentale -Polic.Umberto I -Univ. La Sapienza
    Roma, Rome 00161, Italy
  • Azienda Ospedaliera Umberto I
    Ancona, 60020, Italy
  • Spedali Civili - Universita degli Studi
    Brescia, 25123, Italy
  • Fondazione Universitaria degli Studi G D'Annunzio
    Chieti, 66100, Italy
  • Azienda Ospedaliera di Perugia
    Perugia, 06129, Italy
  • Arcispedale Santa Maria Nuova Azienda Ospedaliera di Reggio Emilia
    Reggio Emilia, 42123, Italy
  • Policlinico di Tor Vergata
    Roma, 00133, Italy
  • Ospedale Policlinico Giambattista Rossi, Borgo Roma
    Verona, 37134, Italy
  • Yanagihara dermatology clinic
    Ainokawa, Ichikawa-shi, Chiba 272-0143, Japan
  • Fumimori Clinic
    Fukuoka-shi, Fukuoka 815-0082, Japan
  • Queen's Square Dermatology and Allergology
    Nishi-ku, Yokohama-city, Kanagawa 220-6208, Japan
  • Noguchi Dermatology
    Kashima-machi, Kamimashiki-gun, Kumamoto 861-3101, Japan
  • Yoshioka Dermatology Clinic
    Neyagawa-shi, Osaka 572-0838, Japan
  • Kume Clinic
    Nishi-ku Sakai-shi, Osaka 593-8324, Japan
  • Sanrui Dermatology Clinic
    Ohmiya-ku,Saitama-shi, Saitama 330-0854, Japan
  • Iidabashi Clinic
    Chiyoda-ku, Tokyo 102-0072, Japan
  • Nihonbashi Sakura Clinic
    Chuo-ku, Tokyo 103-0025, Japan
  • Sumire Dermatology Clinic
    Edogawa-ku, Tokyo 133-0057, Japan
  • Tachikawa Dermatology Clinic
    Tachikawa-shi, Tokyo 190-0023, Japan
  • Academisch Medisch Centrum
    Amsterdam, 1105 AZ, Netherlands
  • Bravis Ziekenhuis
    Bergen op Zoom, 4624 VT, Netherlands
  • Amphia Ziekenhuis
    Breda, 4818 CK, Netherlands
  • NZOZ Specjalistyczna Przychodnia Dermatologiczna Specderm
    Bialystok, 15-375, Poland
  • Centrum Badan Klinicznych, PI House
    Gdansk, 80-546, Poland
  • Centrum Medyczne Angelius Provita
    Katowice, 40-611, Poland
  • Barbara Rewerska DIAMOND CLINIC
    Krakow, 31-559, Poland
  • Dermed Centrum Medyczne Sp. z o.o.
    Lodz, 90-265, Poland
  • Miejski Szpital Zespolony w Olsztynie Klinika Dermatologii
    Olsztyn, 10-229, Poland
  • DermoDent, Centrum Medyczne Czajkowscy
    Osielsko, 86-031, Poland
  • LASER CLINIC Specjalistyczne Gabinety Lekarskie
    Szczecin, 70-332, Poland
  • Wojskowy Instytut Medyczny CSK MON
    Warsaw, 04-141, Poland
  • Centralny Szpital Kliniczny MSW Klinika Dermatologii
    Warszawa, 02-507, Poland
  • State scientific centre for dermatovenerology and cosmetolog
    Moscow, 107076, Russian Federation
  • First Moscow State Medical University n.a. Sechenov
    Moscow, 119991, Russian Federation
  • LLC ArsVitae NorthWest
    Saint-Petersburg, 194223, Russian Federation
  • LLC Medical Center "Kurator"
    Saint-Petersburg, 196240, Russian Federation
  • SPb SBHI Skin-venerologic dispensary #10
    St. Petersburg, 194021, Russian Federation
  • Hospital Universitari de Bellvitge
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Hospital Univ. Puerta de Hierro
    Majadahonda, Madrid 28220, Spain
  • Hospital Universitario Quiron Madrid
    Pozuelo de Alarcon, Madrid 28223, Spain
  • Hospital Universitario de Torrejon
    Torrejón de Ardoz, Madrid 28850, Spain
  • Hospital de Manises
    Manises, Valencia 46940, Spain
  • Hospital De Basurto
    Bilbao, Vizcaya 48013, Spain
  • Hospital Universitario Dr Pesset
    Valencia, 46017, Spain
  • Kantonsspital St. Gallen
    St. Gallen, Sankt Gallen 9007, Switzerland
  • Inselspital Bern
    Bern, 3010, Switzerland
  • Universitätsspital Zürich
    Zürich, 8091, Switzerland
  • Salford Royal NHS Foundation Trust
    Salford, Greater Manchester M6 8HD, United Kingdom
  • West Glasgow Ambulatory Care Hospital
    Glasgow, Lanarkshire G3 8SJ, United Kingdom
  • Whipps Cross University Hospital
    Leytonstone, London E11 1NR, United Kingdom

Showing the first 100 of 103 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Katoh N, Takita Y, Isaka Y, Nishikawa A, Torisu-Itakura H, Saeki H. Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials. Dermatol Ther (Heidelb). 2022 Dec;12(12):2765-2779. doi: 10.1007/s13555-022-00828-5. Epub 2022 Oct 18. PubMed 36255569 ↗
  • King B, Maari C, Lain E, Silverberg JI, Issa M, Holzwarth K, Brinker D, Cardillo T, Nunes FP, Simpson EL. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials. Am J Clin Dermatol. 2021 May;22(3):395-405. doi: 10.1007/s40257-021-00602-x. Epub 2021 Apr 7. PubMed 33826132 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Nov 2019, 18 months.

Results were first posted in Jan 2021, 1 year 1 month after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 18 months is close to that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2018
First posted
Feb 9, 2018
StartActual
May 15, 2018
Primary completionActual
Nov 25, 2019
CompletionActual
Apr 20, 2023
Results first posted
Jan 19, 2021
Last update
May 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03428100
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Feb 9, 2018
Start date
May 15, 2018
Primary completion
Nov 25, 2019
Completion
Apr 20, 2023
Results posted
Jan 19, 2021
Last update
May 14, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion